Rose M et al (2020) PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol 8:564601

Article  PubMed  PubMed Central  Google Scholar 

Yi M et al (2019) Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 8:29

Article  PubMed  PubMed Central  Google Scholar 

Casaubon JT, Kashyap S, Regan JP (2022) BRCA 1 and 2. StatPearls, Treasure Island

Google Scholar 

Tutt ANJ et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394–2405

Article  CAS  PubMed  PubMed Central  Google Scholar 

RayChaudhuri A, Nussenzweig A (2017) The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol 18(10):610–621

Article  CAS  Google Scholar 

Murthy P, Muggia F (2019) PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2019.002

Article  PubMed  PubMed Central  Google Scholar 

Stewart MD et al (2022) Homologous recombination deficiency: concepts, definitions, and assays. Oncologist 27(3):167–174

Article  PubMed  PubMed Central  Google Scholar 

Bryant HE et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917

Article  CAS  PubMed  Google Scholar 

Farmer H et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921

Article  CAS  PubMed  Google Scholar 

Fong PC et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134

Article  CAS  PubMed  Google Scholar 

Tutt A et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244

Article  CAS  PubMed  Google Scholar 

Murai J et al (2014) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13(2):433–443

Article  CAS  PubMed  Google Scholar 

de Bono J et al (2017) Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 7(6):620–629

Article  PubMed  PubMed Central  Google Scholar 

Turner NC et al (2019) A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res 25(9):2717–2724

Article  CAS  PubMed  Google Scholar 

Robson M et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533

Article  CAS  PubMed  Google Scholar 

Robson ME et al (2019) OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 30(4):558–566

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litton JK et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763

Article  CAS  PubMed  Google Scholar 

Litton JK et al (2020) Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31(11):1526–1535

Article  CAS  PubMed  Google Scholar 

Lyons TG, Robson ME (2018) Resurrection of PARP inhibitors in breast cancer. J Natl Compr Cancer Netw 16(9):1150–1156

Article  CAS  Google Scholar 

Domchek SM et al (2020) Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 21(9):1155–1164

Article  CAS  PubMed  Google Scholar 

Chabanon RM et al (2016) Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res 22(17):4309–4321

Article  CAS  PubMed  Google Scholar 

Jiao S et al (2017) PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23(14):3711–3720

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yap TA et al (2020) Abstract P1–19–03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: results from advanced breast cancer cohorts. Cancer Res 80:P1-19-03-P1-19–03

Article  Google Scholar 

Tutt A et al (2022) VP1-2022: pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Ann Oncol 33(5):566–568

Article  Google Scholar 

Litton JK et al (2021) Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): results of a phase 2 study. J Clin Oncol 39(15_suppl):505–505

Article  Google Scholar 

Takamatsu S et al (2022) Utility of homologous recombination deficiency biomarkers across cancer types. JCO Precis Oncol 6:e2200085

Article  PubMed  PubMed Central  Google Scholar 

Tung NM et al (2020) TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 38(36):4274–4282

Article  CAS  PubMed  Google Scholar 

Telli ML et al (2016) Homologous recombination deficiency (HRD) Score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22(15):3764–3773

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fasching PA et al (2021) Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 32(1):49–57

Article  CAS  PubMed  Google Scholar 

Alba KP et al (2020) Abstract P3–10–05: Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. Cancer Res 80(4_Supplement):P3-10-05-P3-10–05

Article  Google Scholar 

Wagner LM (2015) Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther 8:1931–1939

Article  CAS  PubMed  PubMed Central  Google Scholar 

Puhalla S, Beumer J, Pahuja S (2014) Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt) [abstract]. J Clin Oncol 32(Suppl):2570

Article  Google Scholar 

Somlo G, Frankel P, Arun B (2017) Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066–4076

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS et al (2016) Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375(1):23–34

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loibl S et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19(4):497–509

Article  CAS  PubMed  Google Scholar 

Geyer CE et al (2022) Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol 33(4):384–394

Article  CAS  PubMed  Google Scholar 

Vinayak S et al (2019) Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol 5(8):1132–1140

Article  PubMed  PubMed Central  Google Scholar 

Madariaga A et al (2020) Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 30(7):903–915

Article  PubMed  PubMed Central